HUTCHMED Presents Data at AACR NCI EORTC

Summary by AI BETAClose X

HUTCHMED announced preclinical data for HMPL-A251, a first-in-class PI3K/AKT/mTOR-HER2 Antibody-Targeted Therapy Conjugate, at the AACR‑NCI‑EORTC conference. The PI3K/PIKK inhibitor payload demonstrated high potency and broad anti-tumor activity across 130 tumor cell lines in vitro. HMPL-A251 showed HER2-dependent antitumor activity, potently inhibiting HER2-positive tumor cell growth. In vivo, HMPL-A251 demonstrated superior anti-tumor efficacy and tolerability compared to the naked antibody and payload administered together, inducing tumor regression across multiple models after a single intravenous dose. The plasma exposure of free payload was much lower than for HMPL-251, with a mass ratio of less than 1:500,000. HUTCHMED plans to initiate global clinical trials for HMPL-A251 around the end of 2025.

Disclaimer*

UK 100

Latest directors dealings